Literature DB >> 32696323

The effect of a nurse-led prednisolone tapering regimen in polymyalgia rheumatica: a retrospective cohort study.

Christoffer Mørk1, Mette Y Dam1, Mikkel G Callsen1, Kresten K Keller2.   

Abstract

The objective of this study is to investigate the efficacy of a nurse-led prednisolone tapering regime in patients with polymyalgia rheumatica (PMR) compared to standard care. It is a single-center retrospective cohort study evaluating dose and percentage of patients receiving prednisolone after 1 and 2 years. A nurse-led PMR clinic was introduced June 2015 and patients diagnosed until June 2017 were included. Patients were diagnosed by a rheumatologist, and subsequently managed by nurses according to a specific protocol. Patients diagnosed with PMR between June 2012 and June 2015 served as controls. They received standard care by a rheumatologist. Sixty-eight patients received standard care and 107 nurse-led care. After 1 year, 71% of patients receiving standard care vs. 64% receiving nurse-led care took prednisolone (p = 0.441). Median (interquartile range) prednisolone dose after 1 year was 3.75 mg (0-5) in the standard care group and 1.25 mg (0-3.75) in the nurse-led care group (p = 0.004). After 2 years, 41% of patients receiving standard care vs. 18% receiving nurse-led care took prednisolone (p = 0.003). Prednisolone dose after 2 years was 0 mg (0-2.5) in the standard care group and 0 mg (0-0) in the nurse-led care group (p = 0.004). There was no difference regarding relapse and initiation of methotrexate. The number of patient contacts was 12.5 (5-16.5) in the standard care group vs. 17 (13-23) in the nurse-led care group (p = 0.001). A tight and systematic approach to prednisolone tapering is more effective than standard care, but more frequent patient contacts were necessary to obtain this effect.

Entities:  

Keywords:  Nurse-led care; Polymyalgia rheumatica; Prednisolone; Tapering regimen

Year:  2020        PMID: 32696323     DOI: 10.1007/s00296-020-04654-w

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN: 0172-8172            Impact factor:   2.631


  9 in total

Review 1.  Discontinuation of therapies in polymyalgia rheumatica and giant cell arteritis.

Authors:  Francesco Muratore; Nicolò Pipitone; Gene G Hunder; Carlo Salvarani
Journal:  Clin Exp Rheumatol       Date:  2013-10-04       Impact factor: 4.473

2.  Longterm therapy in polymyalgia rheumatica: effect of coexistent temporal arteritis.

Authors:  J Narváez; J M Nolla-Solé; M T Clavaguera; J Valverde-García; D Roig-Escofet
Journal:  J Rheumatol       Date:  1999-09       Impact factor: 4.666

3.  Restricted dose and duration of corticosteroid treatment in patients with polymyalgia rheumatica and temporal arteritis.

Authors:  I Lundberg; E Hedfors
Journal:  J Rheumatol       Date:  1990-10       Impact factor: 4.666

4.  Clinical outcome of 149 patients with polymyalgia rheumatica and giant cell arteritis.

Authors:  S Bahlas; C Ramos-Remus; P Davis
Journal:  J Rheumatol       Date:  1998-01       Impact factor: 4.666

5.  Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial.

Authors:  Catriona Grigor; Hilary Capell; Anne Stirling; Alex D McMahon; Peter Lock; Ramsay Vallance; Wilma Kincaid; Duncan Porter
Journal:  Lancet       Date:  2004 Jul 17-23       Impact factor: 79.321

6.  Polymyalgia rheumatica. Duration of therapy and long-term outcome.

Authors:  W T Ayoub; C M Franklin; D Torretti
Journal:  Am J Med       Date:  1985-09       Impact factor: 4.965

7.  Methotrexate in polymyalgia rheumatica: preliminary results of an open, randomized study.

Authors:  G Ferraccioli; F Salaffi; S De Vita; L Casatta; E Bartoli
Journal:  J Rheumatol       Date:  1996-04       Impact factor: 4.666

8.  2015 Recommendations for the management of polymyalgia rheumatica: a European League Against Rheumatism/American College of Rheumatology collaborative initiative.

Authors:  Christian Dejaco; Yogesh P Singh; Pablo Perel; Andrew Hutchings; Dario Camellino; Sarah Mackie; Andy Abril; Artur Bachta; Peter Balint; Kevin Barraclough; Lina Bianconi; Frank Buttgereit; Steven Carsons; Daniel Ching; Maria Cid; Marco Cimmino; Andreas Diamantopoulos; William Docken; Christina Duftner; Billy Fashanu; Kate Gilbert; Pamela Hildreth; Jane Hollywood; David Jayne; Manuella Lima; Ajesh Maharaj; Christian Mallen; Victor Martinez-Taboada; Mehrdad Maz; Steven Merry; Jean Miller; Shunsuke Mori; Lorna Neill; Elisabeth Nordborg; Jennifer Nott; Hannah Padbury; Colin Pease; Carlo Salvarani; Michael Schirmer; Wolfgang Schmidt; Robert Spiera; David Tronnier; Alexandre Wagner; Madeline Whitlock; Eric L Matteson; Bhaskar Dasgupta
Journal:  Ann Rheum Dis       Date:  2015-10       Impact factor: 19.103

9.  Clinical evaluation of the safety, efficacy and tolerability of sarilumab in the treatment of moderate to severe rheumatoid arthritis.

Authors:  Eleftherios Pelechas; Paraskevi V Voulgari; Alexandros A Drosos
Journal:  Ther Clin Risk Manag       Date:  2019-09-04       Impact factor: 2.423

  9 in total
  2 in total

Review 1.  Long-term glucocorticoid treatment and high relapse rate remain unresolved issues in the real-life management of polymyalgia rheumatica: a systematic literature review and meta-analysis.

Authors:  Alberto Floris; Matteo Piga; Elisabetta Chessa; Mattia Congia; Gian Luca Erre; Maria Maddalena Angioni; Alessandro Mathieu; Alberto Cauli
Journal:  Clin Rheumatol       Date:  2021-08-20       Impact factor: 3.650

2.  Long-term use of glucocorticoids for polymyalgia rheumatica: follow-up of the PMR Cohort Study.

Authors:  Sara Muller; Samantha L Hider; Balamrit Singh Sokhal; Sarah A Lawton; Toby Helliwell; Christian D Mallen
Journal:  Rheumatol Adv Pract       Date:  2022-05-11
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.